Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update
Agenus (NASDAQ: AGEN), a company focused on developing immunological cancer treatments, has scheduled its third quarter 2024 financial results release before market opening on Tuesday, November 12th, 2024. The company will host a conference call and webcast at 8:30 a.m. ET the same day, featuring executive discussions of the results and a corporate update.
Agenus (NASDAQ: AGEN), un'azienda concentrata nello sviluppo di trattamenti immunologici per il cancro, ha programmato la pubblicazione dei suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura del mercato martedì 12 novembre 2024. L'azienda ospiterà una conferenza telefonica e una webcast alle 8:30 a.m. ET dello stesso giorno, con discussioni esecutive sui risultati e un aggiornamento aziendale.
Agenus (NASDAQ: AGEN), una empresa enfocada en desarrollar tratamientos inmunológicos para el cáncer, ha programado la publicación de sus resultados financieros del tercer trimestre de 2024 antes de la apertura del mercado el martes 12 de noviembre de 2024. La empresa llevará a cabo una conferencia telefónica y una transmisión en vivo a las 8:30 a.m. ET ese mismo día, con discusiones ejecutivas sobre los resultados y una actualización corporativa.
Agenus (NASDAQ: AGEN), 면역학적 암 치료 개발에 집중하는 회사는 2024년 11월 12일 화요일 시장 개장 전에 2024년 3분기 재무 결과 발표를 예정하고 있습니다. 같은 날 오전 8:30 ET에 임원들이 결과와 기업 업데이트를 논의하는 전화 회의 및 웹캐스트를 진행할 예정입니다.
Agenus (NASDAQ: AGEN), une entreprise axée sur le développement de traitements immunologiques contre le cancer, a prévu la publication de ses résultats financiers du troisième trimestre 2024 avant l'ouverture des marchés le mardi 12 novembre 2024. L'entreprise accueillera une conférence téléphonique et une retransmission en direct à 8h30 HNE ce même jour, avec des discussions exécutives sur les résultats et une mise à jour sur l'entreprise.
Agenus (NASDAQ: AGEN), ein Unternehmen, das sich auf die Entwicklung immunologischer Krebsbehandlungen konzentriert, hat die Veröffentlichung seiner Finanzergebnisse für das dritte Quartal 2024 vor Markteröffnung am Dienstag, den 12. November 2024, angesetzt. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und Webcast abhalten, bei der die Führungskräfte die Ergebnisse und ein Unternehmensupdate diskutieren werden.
- None.
- None.
Conference Call:
To access dial-in numbers, please register here.
Conference ID: 73242
A live webcast and replay of the conference call will be accessible on the company’s website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/932317413.
About Agenus
Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105935337/en/
Investors
917-362-1370
investor@agenusbio.com
Media
612-839-6748
communications@agenusbio.com
Source: Agenus Inc.
FAQ
When will Agenus (AGEN) release its Q3 2024 earnings?
What time is Agenus (AGEN) Q3 2024 earnings call?
How can I access Agenus (AGEN) Q3 2024 earnings call?
